Video
Author(s):
Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.